NCT00139711View on ClinicalTrials.gov

Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

March 31, 2003

Study Completion Date

June 30, 2006

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Irinotecan

DRUG

Docetaxel

Trial Locations (15)

20052

Pfizer Investigational Site, Monza

20059

Pfizer Investigational Site, Vimercate

20064

Pfizer Investigational Site, Gorgonzola

20070

Pfizer Investigational Site, Melegnano

20133

Pfizer Investigational Site, Milan

21100

Pfizer Investigational Site, Varses

22015

Pfizer Investigational Site, Gravedona

24022

Pfizer Investigational Site, Alzano Lombardo

25123

Pfizer Investigational Site, Brescia

26013

Pfizer Investigational Site, Crema

28021

Pfizer Investigational Site, Borgomanero

46100

Pfizer Investigational Site, Mantova

70126

Pfizer Investigational Site, Bari

80136

Pfizer Investigational Site, Napoli

82100

Pfizer Investigational Site, Benevento

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00139711 - Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter